Bank of America
KLRS

Bank of America’s Kalaris Therapeutics KLRS Stock Holding History

Bank of America’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,704
Closed -$56.6K – 7182
2025
Q4 		$56.6K Buy
6,704
+6,487
+2,989% +$41.5K ﹤0.01% 5805
2025
Q3 		$1.25K Sell
217
-56
-21% -$185 ﹤0.01% 7461
2025
Q2 		$729 Sell
273
-5,151
-95% -$23.3K ﹤0.01% 7590
2025
Q1 		$43.6K Buy
5,424
+4,438
+450% +$43.5K ﹤0.01% 6786
2024
Q4 		$9.52K Sell
986
-63
-6% -$953 ﹤0.01% 6992
2024
Q3 		$19.5K Buy
1,049
+78
+8% +$1.36K ﹤0.01% 6747
2024
Q2 		$16.1K Sell
971
-1,002
-51% -$17.7K ﹤0.01% 6788
2024
Q1 		$34.2K Sell
1,973
-1,078
-35% -$17.6K ﹤0.01% 6626
2023
Q4 		$47.6K Buy
3,051
+1,155
+61% +$45.5K ﹤0.01% 6611
2023
Q3 		$93.7K Buy
1,896
+707
+59% +$48.2K ﹤0.01% 6272
2023
Q2 		$93K Sell
1,189
-25
-2% -$2.38K ﹤0.01% 6234
2023
Q1 		$110K Sell
1,214
-91
-7% -$11.6K ﹤0.01% 6220
2022
Q4 		$154K Buy
1,305
+693
+113% +$118K ﹤0.01% 6053
2022
Q3 		$111K Sell
612
-287
-32% -$44.7K ﹤0.01% 6296
2022
Q2 		$81K Sell
899
-117
-12% -$12.3K ﹤0.01% 6583
2022
Q1 		$158K Sell
1,016
-3,779
-79% -$754K ﹤0.01% 6611
2021
Q4 		$1.43M Buy
4,795
+4,180
+680% +$1.94M ﹤0.01% 4905
2021
Q3 		$355K Sell
615
-100
-14% -$46.3K ﹤0.01% 5890
2021
Q2 		$325K Sell
715
-655
-48% -$338K ﹤0.01% 5748
2021
Q1 		$738K Buy
1,370
+1,248
+1,023% +$1.05M ﹤0.01% 5070
2020
Q4 		$108K Buy
122
+79
+184% +$60.8K ﹤0.01% 5948
2020
Q3 		$27K Buy
+43
New +$29.4K ﹤0.01% 6222

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America's KLRS Position: Q1 2026 in Review

Bank of America sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 6,704 shares — an estimated $56.6K sold.

Bank of America first reported a position in KLRS in Q3 2020 and held it in 22 quarters. The position peaked at $1.43M in Q4 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Bank of America reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 6,704 Kalaris Therapeutics shares in Q1 2026, an estimated $56.6K.
  • Bank of America first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 22 quarters.
  • Bank of America's Kalaris Therapeutics position peaked at $1.43M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.